v3.26.1
Consolidated Statements of Cash Flows - USD ($)
$ in Thousands
 12 Months Ended
Mar. 31, 2026
Mar. 31, 2025
Cash flows from operating activities:    
Net loss $ (7,793) $ (9,568)
Adjustments:    
Depreciation expense 7 7
Loss on disposal 0 2
Stock-based compensation 798 730
Change in fair value of derivative warrant liabilities (900) (3,218)
Deferred income tax benefit (1,700) (3,199)
Changes in operating assets and liabilities:    
Receivables 106 596
Prepaid expenses 70 (170)
Trade and other payables 543 (84)
Net cash used in operating activities (8,869) (14,904)
Cash flows from investing activities:    
Maturity of short-term investments 0 15
Purchase of short-term investments 0 (15)
Net cash provided by investing activities 0 0
Cash flows from financing activities:    
Gross proceeds from issuance of common stock and warrants from private placement 0 14,999
Stock issuance costs (327) (967)
Proceeds from issuance of common stock from common warrant exercise 4,040 0
Net cash provided by financing activities 3,713 14,032
Net decrease in cash and cash equivalents (5,156) (872)
Cash and cash equivalents, beginning of year 22,133 23,005
Cash and cash equivalents, end of year 16,977 22,133
Cash and cash equivalents are comprised of:    
Cash 1,307 830
Cash equivalents 15,670 21,303
Supplemental schedule of non-cash financing activities are comprised of:    
Issuance costs in accounts payable 0 327
Settlement of derivative warrant liability $ 241 $ 0